242 related articles for article (PubMed ID: 35453363)
1. Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders.
Kaczor-Kamińska M; Kamiński K; Wróbel M
Antioxidants (Basel); 2022 Mar; 11(4):. PubMed ID: 35453363
[TBL] [Abstract][Full Text] [Related]
2. Effect of glycosaminoglycans accumulation on the non-oxidative sulfur metabolism in mouse model of Sanfilippo syndrome, type B.
Kaczor-Kamińska M; Kamiński K; Stalińska K; Wróbel M; Feldman A
Acta Biochim Pol; 2019 Dec; 66(4):567-576. PubMed ID: 31805227
[TBL] [Abstract][Full Text] [Related]
3. Murine cellular model of mucopolysaccharidosis, type IIIB (MPS IIIB) - A preliminary study with particular emphasis on the non-oxidative l-cysteine metabolism.
Kaczor-Kamińska M; Stalińska K; Kamiński K; Pisarek A; Maziarz U; Feldman A; Wróbel M
Biochimie; 2020 Jul; 174():84-94. PubMed ID: 32335228
[TBL] [Abstract][Full Text] [Related]
4. Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B.
Prill H; Luu A; Yip B; Holtzinger J; Lo MJ; Christianson TM; Yogalingam G; Aoyagi-Scharber M; LeBowitz JH; Crawford BE; Lawrence R
Mol Ther Methods Clin Dev; 2019 Sep; 14():56-63. PubMed ID: 31309128
[TBL] [Abstract][Full Text] [Related]
5. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)].
Zhang WM; Shi HP; Meng Y; Li BT; Qiu ZQ; Liu JT
Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):407-10. PubMed ID: 19099774
[TBL] [Abstract][Full Text] [Related]
6. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient.
Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D
Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis type III (subtype IIIB) diagnosis as a spectrum disorder: A case report from Kosovo.
Spahiu L; Behluli E; Hadziselimovic R; Liehr T; Temaj G
Folia Med (Plovdiv); 2023 Feb; 65(1):161-165. PubMed ID: 36855989
[TBL] [Abstract][Full Text] [Related]
8. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
Yogalingam G; Hopwood JJ
Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
[TBL] [Abstract][Full Text] [Related]
10. Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
Aoyagi-Scharber M; Crippen-Harmon D; Lawrence R; Vincelette J; Yogalingam G; Prill H; Yip BK; Baridon B; Vitelli C; Lee A; Gorostiza O; Adintori EG; Minto WC; Van Vleet JL; Yates B; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Fitzpatrick PA; LeBowitz JH; Bullens S; Crawford BE; Bunting S
Mol Ther Methods Clin Dev; 2017 Sep; 6():43-53. PubMed ID: 28664165
[TBL] [Abstract][Full Text] [Related]
11. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
[TBL] [Abstract][Full Text] [Related]
12. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
[TBL] [Abstract][Full Text] [Related]
13. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
[TBL] [Abstract][Full Text] [Related]
14. EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB.
De Pasquale V; Pezone A; Sarogni P; Tramontano A; Schiattarella GG; Avvedimento VE; Paladino S; Pavone LM
Cell Death Dis; 2018 Jan; 9(2):40. PubMed ID: 29348482
[TBL] [Abstract][Full Text] [Related]
15. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
[TBL] [Abstract][Full Text] [Related]
16. Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis type IIIB.
Losada JC; Triana H; Venegas E; Caro A; Rodríguez-López A; Espejo-Mojica AJ; Almeciga-Diaz CJ
Chembiochem; 2024 Jun; ():e202400081. PubMed ID: 38830828
[TBL] [Abstract][Full Text] [Related]
17. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
[TBL] [Abstract][Full Text] [Related]
18. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
[TBL] [Abstract][Full Text] [Related]
19. Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice.
Clarke D; Pearse Y; Kan SH; Le SQ; Sanghez V; Cooper JD; Dickson PI; Iacovino M
Mol Ther Methods Clin Dev; 2018 Sep; 10():113-127. PubMed ID: 30101150
[TBL] [Abstract][Full Text] [Related]
20. Effect of S-Allyl -L-Cysteine on MCF-7 Cell Line 3-Mercaptopyruvate Sulfurtransferase/Sulfane Sulfur System, Viability and Apoptosis.
Bronowicka-Adamska P; Bentke A; Lasota M; Wróbel M
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
